Topotecan monotherapy is indicated for the treatment of: • patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. • patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1). Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment-free interval to justify treatment with the combination (see section 5.1).
The FDA has accepted for filing Actavis' supplemental New Drug Application (sNDA) to expand the label for Teflaro (ceftaroline fosamil)...
Actavis plc announced that it will adopt a new corporate name - Allergan - following the anticipated successful completion of...
Actavis plc announced that it has launched its generic version of AstraZeneca's Pulmicort Respules (budesonide inhalation suspension) 0.25 and 0.5...
Actavis plc and Gedeon Richter Plc have announced that the FDA has acknowledged receipt of Actavis' New Drug Application (NDA)...
Vivus Inc has announced that Actavis Plc plans to market a generic version of Qsymia (phentermine plus topiramate).Actavis has already...